Tag : Palivizumab

Cardiology

Palivizumab for Infection Prevention in Inuit Infants: A Review of the Clinical Effectiveness and Cost-Effectiveness

Newsemia
Palivizumab for Infection Prevention in Inuit Infants: A Review of the Clinical Effectiveness and Cost-Effectiveness Book. 2019 12 17 Authors: la Fleur P, Argáez C...
Cardiology

Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series.

Newsemia
Related Articles Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series. Hum Vaccin Immunother. 2020 Sep 22;:1-4 Authors: Takeuchi M,...
Pediatrics

Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports

Newsemia
The only pharmacologic prophylaxis against respiratory syncytial virus (RSV) infection in preterm infants is the humanized monoclonal antibody palivizumab. After the 2014 modification of the...
Cardiology

Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.

Newsemia
Related Articles Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab. Eur J Clin Microbiol Infect Dis. 2019...
Pediatrics

Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection—A Cost-Effectiveness Analysis

Newsemia
ABSTRACT Aim To evaluate the cost-effectiveness of palivizumab prophylaxis for premature infants born <29 weeks in Hong Kong. Method We evaluated the hospitalization rate for...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy